Investigating the effect of inhaled verapamil on pulmonary artery systolic pressure in patients with chronic obstructive pulmonary disease

Phase 3

Recruiting

• Conditions: chronic obsrtuctive pulmonary disease.; Other secondary pulmonary hypertension; I27.2

• Registration Number: IRCT20230804059027N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 August 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

Patients with proven chronic obstructive pulmonary disease based on spirometry criteria and patient history
Patients with proven chronic obstructive pulmonary disease and hospitalized in Imam Khomeini Hospital

Exclusion Criteria

Valvular heart disease more than moderate
Pulmonary valve stenosis
History of renal failure
History of liver cirrhosis
History of pulmonary embolism
Congenital heart disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pulmonary artery systolic pressure reduction. Timepoint: Pulmonary artery systolic pressure was measured by echocardiography at the beginning of the study (before the intervention) and 1 hour after receiving inhaled verapamil. Method of measurement: Echocardiography device Affiniti 50.

Secondary Outcome Measures

Name	Time	Method
The increase in oxygen saturation of arterial blood. Timepoint: Arterial blood oxygen saturation is measured before receiving inhaled verapamil (pre-intervention) and 1 hour after the intervention. Method of measurement: Measurement of arterial blood oxygen saturation is done by finger pulse oximeter.